TY  - GEN
AU  - Adams,S
AU  - Loi,S
AU  - Toppmeyer,D
AU  - Cescon,D W
AU  - De Laurentiis,M
AU  - Nanda,R
AU  - Winer,E P
AU  - Mukai,H
AU  - Tamura,K
AU  - Armstrong,A
AU  - Liu,M C
AU  - Iwata,H
AU  - Ryvo,L
AU  - Wimberger,P
AU  - Rugo,H S
AU  - Tan,A R
AU  - Jia,L
AU  - Ding,Y
AU  - Karantza,V
AU  - Schmid,P
TI  - Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study
SN  - 1569-8041
PY  - 2020///0324
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antibodies, Monoclonal, Humanized
KW  - administration & dosage
KW  - B7-H1 Antigen
KW  - genetics
KW  - Cohort Studies
KW  - Female
KW  - Gene Expression Regulation, Neoplastic
KW  - drug effects
KW  - Humans
KW  - Middle Aged
KW  - Neoplasm Metastasis
KW  - Progression-Free Survival
KW  - Triple Negative Breast Neoplasms
KW  - drug therapy
N1  - Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1093/annonc/mdy518
ER  -